Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia

References

• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019 Jul;36:70–87. doi:https://doi.org/10.1016/j.blre.2019.04.005.
   PubMed Web of Science ®Google Scholar
• Institute NC. Cancer stat facts: acute myeloid leukemia (AML) 2020 [Cited 2021 Jun 3.]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html
   Google Scholar
• DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukemia (AG221-AML-005): a single-arm, phase 1b, randomized phase 2 trial. Lancet Oncol. 2021 Nov;22(11):1597–1608.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Lin TL, Uy GL, et al. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. J Hematol Oncol. 2021 Jul 13 14(1):110.
   PubMed Web of Science ®Google Scholar
• Huls G, Chitu DA, Havelange V, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. 2019 Mar 28 133(13):1457–1464.
   PubMedGoogle Scholar
• Medeiros BC, Chan SM, Daver NG, et al. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol. 2019 Jul;94(7):803–811.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Frech P, Weber D, et al. Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia. 2017 May;31(5):1217–1220.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26 129(4):424–447.
   PubMedGoogle Scholar
• DiNardo CD, Lachowiez CA, Takahashi K, et al. venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021 Sep 1 39(25):2768–2778.
   PubMedGoogle Scholar
• Molica M, Breccia M, Foa R, et al. Maintenance therapy in AML: the past, the present and the future. Am J Hematol. 2019 Nov;94(11):1254–1265.
   PubMed Web of Science ®Google Scholar
• Blum W, Sanford BL, Klisovic R, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 cancer and leukemia group B study (CALGB 10503). Leukemia. 2017 Jan;31(1):34–39.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 Aug 13 383(7):617–629.
   PubMedGoogle Scholar
• Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20 29(18):2521–2527.
   PubMedGoogle Scholar
• Laille E, Shi T, Garcia-Manero G, et al. Pharmacokinetics and pharmacodynamics with extended dosing of cc-486 in patients with hematologic malignancies. PLoS One. 2015;10(8):e0135520.
   PubMed Web of Science ®Google Scholar
• Savona MR, Kolibaba K, Conkling P, et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am J Hematol. 2018 Oct;93(10):1199–1206.
   PubMed Web of Science ®Google Scholar
• Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020 Dec 24 383(26):2526–2537.
   PubMedGoogle Scholar
• FDA. FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia Sep 2020 [Cited 2021 Jun 2]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-onureg-azacitidine-tablets-acute-myeloid-leukemia
   Google Scholar
• Stein EM, Bonifacio G, Latremouille-Viau D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and medicare populations. J Med Econ. 2018 Jun;21(6):556–563.
   PubMed Web of Science ®Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011 Oct 10; 11:139
   PubMedGoogle Scholar
• Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014 Feb;32(2):101–108.
   PubMed Web of Science ®Google Scholar
• Arias E, Bastian B, Xu J, et al. U.S. State Life Tables, 2018. Natl Vital Stat Rep. 2021 Mar;70(1):1–18.
   Google Scholar
• Tallman M, Lo-Coco F, Barnes G, et al. Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxide and retinoic acid in the United States. Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):771–777.
   PubMedGoogle Scholar
• Stein E, Xie J, Duchesneau E, et al. cost effectiveness of midostaurin in the treatment of newly diagnosed flt3-mutated acute myeloid leukemia in the United States. PharmacoEconomics. 2019 Feb;37(2):239–253.
   PubMed Web of Science ®Google Scholar
• Stein EM, Yang M, Guerin A, et al. Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States. Health Qual Life Outcomes. 2018 Sep 21 16(1):193.
   PubMedGoogle Scholar
• Bell JA, Galaznik A, Farrelly E, et al. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018 Aug;71:27–33.
   PubMed Web of Science ®Google Scholar
• Drugs C [Accessed June 2,2021].Available from: https://www.drugs.com/price-guide/onureg.
   Google Scholar
• Wong W, Yim Y, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PloS one. 2018;13(4):e0196007.
   PubMed Web of Science ®Google Scholar
• GoodRx. [Cited 2021 Jun]. Available from: www.goodrx.com.
   Google Scholar
• Hill G, Barron R, Fust K, et al. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses. Journal of Medical Economics. 2014;17(1):32–42.
   PubMedGoogle Scholar
• Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol. 2002 May 15 20(10):2441–2452.
   PubMedGoogle Scholar
• Labor. UDo. Calculators. 2018 [ Accessed June 2,2021]. Available from: http://www.bls.gov/data/#calculators
   Google Scholar
• Levy AR, Zou D, Risebrough N, et al. Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes. Curr Oncol. 2014 Feb;21(1):e29–40.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. Jama. 2016 Sep 13 316(10):1093–1103.
   PubMedGoogle Scholar
• Sato T, Issa JJ, Kropf P. DNA hypomethylating drugs in cancer therapy. Cold Spring Harb Perspect Med. 2017 May 1; 7(5):a026948.
   PubMedGoogle Scholar
• Zhang W, Xu J. DNA methyltransferases and their roles in tumorigenesis. Biomark Res. 2017;5:1.
   PubMed Web of Science ®Google Scholar
• Cojocari D, Smith BN, Purkal JJ, et al. Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 2021 Apr 15;https://doi.org/10.3324/haematol.2020.272609
   Google Scholar
• Coyle D, Villeneuve PJA. Economic Evaluation Of Azacitidine In Elderly Patients With Acute Myeloid Leukemia With High Blast Counts. Pharmacoecon Open. 2020 Jun;4(2):297–305.
   PubMed Web of Science ®Google Scholar
• Patel KK, Zeidan AM, Shallis RM, et al. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv. 2021 Feb 23 5(4):994–1002.
   PubMedGoogle Scholar
• Cao Y, Zhao L, Zhang T, et al. Cost-effectiveness analysis of adding daratumumab to bortezomib, melphalan, and prednisone for untreated multiple myeloma. Front Pharmacol. 2021;12:608685.
   PubMed Web of Science ®Google Scholar
• Burki TK A new strategy to reduce US drug prices. Lancet Oncol. 2018 May 17;18(S1470–2045):30374–7.
   Google Scholar
• Prasad V, Jesús K D, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017 Jun;14(6):381–390.
   PubMed Web of Science ®Google Scholar